American Society of Hirudotherapy

Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii

Research article published in The Biochemical journal (1997)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Preclinical (animal)Genomics & ProteomicsSalivary PharmacologyFinney S et al. · The Biochemical journal, 1997

Abstract

1. Crude salivary gland extract of the giant Amazon leech, Haementeria ghilianii, contains an inhibitor of plasma factor XIIIa. 2. The inhibitory agent was purified to homogeneity by anion-exchange, cation-exchange, gel-filtration and reverse-phase chromatography to yield a single band on SDS/PAGE with an apparent molecular mass of 7.3 kDa. It has been named tridegin. 3. Micro-sequencing of proteolytic fragments showed tridegin to be a peptide of 66 amino acids. The sequence is unique with little similarity to other leech-derived proteins. 4. Inhibition of plasma factor XIIIa activity was confirmed by four independent methods: tridegin increased the solubility of fibrin clots in urea, inhibited ammonia produced from the incorporation of ethylamine into casein, inhibited the incorporation of 5'-(biotinamido)pentylamine into casein and prevented gamma-dimer formation in clotting fibrinogen. 5. The IC50 of tridegin (approx. 9.2 nM) is very close to the concentration of factor XIIIa used in the assay and in fact depends on its concentration. This is the most potent inhibitor of factor XIIIa yet described. 6. Tridegin also inhibits platelet factor XIIIa (factor XIIIAa) with a similar potency to that of the plasma enzyme. 7. Tridegin also inhibits tissue transglutaminase but with lower potency and independently of the enzyme concentration. 8. Tridegin appears to be specific for transglutaminases, since it has no effect on the coagulation times of human plasma, on thrombin or factor Xa. Moreover it has no effect on other thiol-containing enzymes and has no ability to digest fibrinogen or cleave the isopeptide substrate, L-gamma-glutamyl-4-nitroanilide.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAmino Acid SequenceAmmoniaAnimalsChromatography, GelChromatography, Ion ExchangeElectrophoresis, Polyacrylamide GelEnzyme InhibitorsFactor XaFibrinFibrinolysisGlutamineGuinea PigsHumansLeechesLiverMolecular Sequence DataSalivary GlandsSalivary Proteins and PeptidesThrombinTransglutaminases

Summary

A 66-amino-acid peptide named tridegin was purified from the salivary glands of the Amazon leech Haementeria ghilianii; it inhibits plasma factor XIIIa with an IC50 of approximately 9.2 nM without affecting thrombin or factor Xa.

Why This Matters for Hirudotherapy

This study isolated and characterized tridegin, a novel 66-amino-acid peptidic inhibitor of factor XIIIa from the giant Amazon leech Haementeria ghilianii, purified from crude salivary gland extract through multiple chromatographic steps to yield a 7.3 kDa homogeneous protein with a unique sequence showing little similarity to other leech-derived proteins. Tridegin inhibited plasma and platelet factor XIIIa with an IC50 of approximately 9.2 nM—the most potent factor XIIIa inhibitor described—and was confirmed by four independent methods including increased fibrin clot solubility in urea and prevention of gamma-dimer formation. The study identifies a novel bioactive molecule from leech saliva with a unique mechanism targeting fibrin crosslinking, distinct from anticoagulant and antiplatelet activities of other leech proteins. However, the study is entirely in vitro with no animal or clinical data.

Citation

Reference (Vancouver style)

Finney S, Seale L, Sawyer RT, Wallis RB. Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii. Biochem J. 1997;324 (Pt 3)(Pt 3):797-805. doi:10.1042/bj3240797. PMID: 9210403

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.